You just read:

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab as the First-line Treatment for Patients with NSCLC at Annual Meeting of the Chinese Society of Clinical Oncology

News provided by

Innovent Biologics, Inc.

Sep 19, 2018, 22:45 ET